Novartis Ag ADR (NVS) Stock Price, Quote & News

Company Profile

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 41 61 324 11 11

Fax: 41 61 324 80 01

Website: www.novartis.com

Address:

Lichtstrasse 35, Basel, Switzerland

TheLocoPro Aug. 23 at 7:37 PM

$APUS they already have an FDA approved pain treatment and there is a reason why they just added new management with big ties to $NVS A stock valued at $245 Billion. This doesn’t happen for no reason. Big news is likely to come out any day.

0 · Reply

clan Aug. 22 at 10:25 PM

$MNKD For all the Lasagna-haters trolling this board ... One day, this could be a division of $AMGN $MRK or $NVS

1 · Reply

wwmeinc Aug. 22 at 4:00 PM

$RNA ...Ahhh....the penny by penny climb to surpass the 52 wk high before the real 'premium' kicks in...Whatever happened to that AH buyer of $48.50 :)? They could have juiced up this climb a bit faster...but no matter...the finish line is within sight...even as the cone of silence is working as intended....The leak or heads-up might have opened the door to other potential suitors though... $BMY has a logical case...but $ARGX might be around but at $40B or so M/C and cash of around $3.5B...fire-power might not measure up to the $NVS of the pharma world...just some thoughts while the mkt goes thru the roof today ;) Good trading and glta. https://whalewisdom.com/stock/rna

1 · Reply

TapePulse Aug. 22 at 3:29 AM

$NVS Swiss pharma company spinning off Sandoz generics business and focusing on innovative medicines

0 · Reply

TechTraderGrok Aug. 21 at 8:14 PM

Bought $NVS at $126.84. From Grok: "Entering long on bounce from rising support at ~126.58 in clear uptrend with EMA above SMA and price above both, no immediate catalysts, targeting resistance near BB upper ~127.50+ for weeks-long hold." https://www.techtrader.ai/grokwall/?post=14568&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

DavyDaveCharts Aug. 21 at 3:36 PM

$NVS weekly: despite the break out, remains not oversold with crossovers on the stochastic RSI and MACDs. Room for more.

0 · Reply

outlawinvestor1 Aug. 21 at 3:32 PM

$RADX nice table of historical comps in radiopharm. we’re super early here! $NVS $BMY $LNTH $CATX

1 · Reply

clan Aug. 21 at 6:55 AM

$MNKD Will Novartis $NVS , with its $241B market cap., have an interest to get back in the Clofazimine game? Asking for friends at $GSK and $AMGN

1 · Reply

Deblitorator Aug. 20 at 7:23 PM

$APUS swinging this long. They have no debt at all with plenty of cash. Looks like they are building a dream team here bringing in management from Gilead Sciences + the same guy who sold Corthera to $NVS

0 · Reply

Slitherin Aug. 20 at 2:11 PM

$LLY is the biggest biotech company out there . Ticker APUS will be next to have a big move. Imagine getting in a startup before it has the potential to 10X. This Penny stock just brought on an executive with connections to $NVS Novartis which is a $240B corporation. They have created a breakthrough pain treatment using bee venom which is a non narcotic and non addictive solution. This is HUGE!

0 · Reply

New Novartis ESC data highlights strength of cardiovascular portfolio

Aug 12, 2025, 1:15 AM EDT - 12 days ago

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Aug 11, 2025, 10:40 AM EDT - 13 days ago

Swiss government to meet pharma firms to discuss US tariffs

Aug 11, 2025, 1:43 AM EDT - 13 days ago

Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease

Aug 11, 2025, 1:20 AM EDT - 13 days ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

Aug 6, 2025, 11:41 AM EDT - 18 days ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

RNA

Aug 1, 2025, 12:01 PM EDT - 23 days ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GILD GSK JNJ

Aug 1, 2025, 8:31 AM EDT - 23 days ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 23 days ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 4:30 PM EDT - 24 days ago

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Jul 31, 2025, 3:35 PM EDT - 24 days ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 3:00 PM EDT - 24 days ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:28 PM EDT - 24 days ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:19 PM EDT - 24 days ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN BMY

Jul 31, 2025, 1:48 PM EDT - 24 days ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 25, 2025, 1:49 PM EDT - 4 weeks ago

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

JNJ LLY

Jul 24, 2025, 8:11 AM EDT - 4 weeks ago

Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies

Jul 24, 2025, 7:30 AM EDT - 4 weeks ago

Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases

Jul 21, 2025, 2:50 AM EDT - 4 weeks ago

Novartis AG (NVS) Q2 2025 Earnings Call Transcript

Jul 17, 2025, 3:45 PM EDT - 5 weeks ago

Novartis CEO: We're in open discussions with the Trump administration

Jul 17, 2025, 11:48 AM EDT - 5 weeks ago

Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan

Jul 17, 2025, 11:43 AM EDT - 5 weeks ago

Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price

Jul 17, 2025, 9:11 AM EDT - 5 weeks ago

Novartis raises outlook on strong second-quarter sales

Jul 17, 2025, 9:10 AM EDT - 5 weeks ago

Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Jul 17, 2025, 3:45 AM EDT - 5 weeks ago

Novartis lifts full-year profit forecast, announces $10 billion share buyback

Jul 17, 2025, 1:11 AM EDT - 5 weeks ago

Novartis slightly raises 2025 earnings forecast, citing strong Q2

Jul 17, 2025, 1:05 AM EDT - 5 weeks ago

Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company

Jul 17, 2025, 1:00 AM EDT - 5 weeks ago

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance

Jul 16, 2025, 9:16 AM EDT - 5 weeks ago

Novartis cannot block generic version of Entresto, judge rules

Jul 13, 2025, 10:45 AM EDT - 6 weeks ago

Why Novartis Is Still A 'Buy' After 15% Surge

Jul 11, 2025, 12:27 PM EDT - 6 weeks ago

Novartis loses bid to block US Entresto generic through 2026

Jul 8, 2025, 1:36 AM EDT - 6 weeks ago

Novartis gets approval for first malaria drug for babies and children

Jul 8, 2025, 1:15 AM EDT - 6 weeks ago

Novartis receives approval for first malaria medicine for newborn babies and young infants

Jul 3, 2025, 1:42 AM EDT - 7 weeks ago

Novartis drug Cosentyx fails late-stage trial for artery disease

Jul 3, 2025, 1:25 AM EDT - 7 weeks ago

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Jun 26, 2025, 1:22 PM EDT - 2 months ago

Final Trades: Novartis, Sixth Street, Amazon and the IYF

AMZN IYF TSLY

Jun 26, 2025, 6:30 AM EDT - 2 months ago

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

Jun 25, 2025, 9:13 AM EDT - 2 months ago

Novartis completes acquisition of Regulus Therapeutics

RGLS

Jun 25, 2025, 7:00 AM EDT - 2 months ago

Novartis: A SWAN Worth Owning

Jun 25, 2025, 1:00 AM EDT - 2 months ago

Novartis announces expiration of Regulus Therapeutics tender offer

RGLS

Jun 12, 2025, 2:25 PM EDT - 2 months ago

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

Jun 12, 2025, 2:00 AM EDT - 2 months ago

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

Jun 2, 2025, 3:20 AM EDT - 2 months ago

Novartis' Pluvicto shown to slow prostate cancer in earlier setting

Jun 2, 2025, 2:04 AM EDT - 2 months ago

Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial

Jun 2, 2025, 1:15 AM EDT - 2 months ago

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

May 28, 2025, 12:22 PM EDT - 3 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN SDGR

May 27, 2025, 7:56 AM EDT - 3 months ago

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

RGLS

May 20, 2025, 7:30 AM EDT - 3 months ago

If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)

NVO

May 15, 2025, 9:00 AM EDT - 3 months ago

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

May 12, 2025, 3:54 PM EDT - 3 months ago

Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know

ABBV GSK JNJ LLY MRK NVO PFE

TheLocoPro Aug. 23 at 7:37 PM

0 · Reply

clan Aug. 22 at 10:25 PM

$MNKD For all the Lasagna-haters trolling this board ... One day, this could be a division of $AMGN $MRK or $NVS

1 · Reply

wwmeinc Aug. 22 at 4:00 PM

1 · Reply

TapePulse Aug. 22 at 3:29 AM

$NVS Swiss pharma company spinning off Sandoz generics business and focusing on innovative medicines

0 · Reply

TechTraderGrok Aug. 21 at 8:14 PM

0 · Reply

DavyDaveCharts Aug. 21 at 3:36 PM

$NVS weekly: despite the break out, remains not oversold with crossovers on the stochastic RSI and MACDs. Room for more.

0 · Reply

outlawinvestor1 Aug. 21 at 3:32 PM

$RADX nice table of historical comps in radiopharm. we’re super early here! $NVS $BMY $LNTH $CATX

1 · Reply

clan Aug. 21 at 6:55 AM

$MNKD Will Novartis $NVS , with its $241B market cap., have an interest to get back in the Clofazimine game? Asking for friends at $GSK and $AMGN

1 · Reply

Deblitorator Aug. 20 at 7:23 PM

0 · Reply

Slitherin Aug. 20 at 2:11 PM

0 · Reply

Slitherin Aug. 20 at 2:08 PM

$VKTX nice bounce Ticker APUS will be next to have a big move. Imagine getting in a startup before it has the potential to 10X. This Penny stock just brought on an executive with connections to $NVS Novartis which is a $240B corporation.

0 · Reply

Quantumup Aug. 19 at 6:49 PM

Canaccord Genuity⬆️ $PVLA's PT to $66 from $52 & reit'd at a Buy. $NVS $TARA $MRK $PFE Canaccord Genuity said in its research report: $PVLA's 2Q25 earnings report was incremental following enrollment completion of its phase 3 SELVA trial for mLM, which exceeded its target (n=40) by over 25% (n=51). Top-line results are on track for 1Q26. Ahead of this readout, the most FAQ investor Q has been around Ph3 design + regulatory risk. We continue to be very comfortable with the former - as a reminder, the trial had 99% power to detect a .5 (vs. 2.42 effect size in Ph2) difference on the primary endpoint before the over enrollment. On the latter, we remain comfortable with the single-arm trial design and see no outsized clinical risk here (vs. the broader biotech space). Results of the phase 2 TOIVA trial for the co's 2nd indication, CVM, remain on track for 4Q25. The company plans to announce both a third clinical indication for QTORIN rapamycin and a second QTORIN platform candidate in 4Q25.

0 · Reply

Quantumup Aug. 19 at 12:08 PM

Piper Sandler🏁 $DAWN Overweight-$25 and said, Investor sentiment has declined following the first two 2025 earnings reports given concern around the potential plateauing of Ojemda ~1 year into launch. $RHHBY $NVS $PFE $BMY ALPMY Piper Sandler additionally said in its $DAWN initiation: We think the stock move is overdone and that these early decelerations are simply artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies. And while the growth may be more gradual that the Street originally expected, we continue to believe the clinical data will support strong penetration longer term.

1 · Reply

StockfatherOG Aug. 19 at 9:42 AM

$APUS they just added management that has major connections to $NVS - $250B MC company . They appointed a CFO right before this. Big things coming

0 · Reply

Quantumup Aug. 18 at 5:35 PM

H.C. Wainwright⬆️ $PVLA's PT to $75 from $38 and reiterated at a Buy rating. $NVS $TARA $SWTX/ ARQL - $MRK PFE H.C. Wainwright said in its research report:

0 · Reply

wwmeinc Aug. 18 at 2:29 PM

$RNA ....Next Monday August 25/25...UK bank holiday...just saying/noting...Would be 'helpful' if $NVS just fulfils their part of the FT.com rumour/story/report this week and seal the $RNA buy out deal...change of control most likely in place for all Avidity Exec's....so they will be well taken care of...and with that out of the way...and after NVS mgmt Inv. bankers dropped the hammer on having anymore 'leaks' to the media...nothing really in the way now for closing this buy-out...oh....I believe we are all expecting something around ~$9B or so...always the possibility of another bidder as well...say... $BMY . All eyes/investment dollars and patient's hope's/dreams will be here though for DMD...safe and efficacy will be their headline. Patiently waiting...with all the risk/rewards that are known ;). Good trading and glta. https://optioncharts.io/options/RNA

0 · Reply

Quantumup Aug. 18 at 12:28 PM

H.C. Wainwright⬆️ $CELC's PT to $66 from $50, reit'd Buy and and said that recent 'Topline Data From The WT Cohort Are Very Supportive Of FDA Approval' after Celcuity reported 2Q25 financial and operating results. $AZN $PFE $RHHBY $NVS ARVN LLY H.C. Wainwright said in its note: Management confirmed that the company plans to submit a new drug application (NDA) by year-end based on data from the PIK3CA wild-type (WT) cohort of the Phase 3 VIKTORIA-1 study of gedatolisib + fulvestrant At palbociclib for treatment of HR+/HER2- advanced breast cancer in CDK4/6-pretreated patients. We believe the recently disclosed topline data from the WT cohort are very supportive of FDA approval. If successful, the drug could receive marketing approval by mid-2026. H.C. Wainwright additionally said:

0 · Reply

Pepper214 Aug. 17 at 8:35 PM

$NVS Novartis has a Cancer Drug that stops and reverses Alzheimers

1 · Reply

GreenEnergy2022 Aug. 17 at 3:49 PM

$ALT $NVO Novo vs ALT comparison. ALT phs3 MASH ready with GLP1. The data is impressive - achieved results almost as good as NOVO. And achieved that even in a 24w study, vs Novo with 72w (!) Weight loss 6% in 24w, and they didnt even run the highest 2.4mg dose. MASH data also impressive, we got glucagon receptors in the liver, and this GLP1 have a ratio of 1:1 glucagon. $PFE $NVS $SNY

1 · Reply

fred898w Aug. 17 at 5:49 AM

$NVS back to 118 next week

1 · Reply

Quantumup Aug. 15 at 4:22 PM

Stifel⬆️the PT on $CELC to $68 from $65 and keeps at a Buy rating. $AZN $PFE $RHHBY $NVS ARVN LLY Stifel said in its note to investors:

0 · Reply

wwmeinc Aug. 15 at 1:21 PM

$RNA .....Looks like July 25/25...was the potential first 'signal'.....everything before seems normal in vol. and number of trades...Is this somebody(bio_clouseau) looking for cheap shares? If there was no smoke here then logic would ask why are the shares still up from the $30's??? As the patient scene is pointing to a SRPT/RNA battle for patients....RNA does have the cash and shareprice and just as important...they have the products/data that look good to gain approval(the one missing piece).......a flip of the coin as in any buy-out scenario....I like the $10...risk/reward by holding and adding if it drops back below $32......just some thoughts as we all await $RNA and $NVS and/or $BMY .....or whomever....Merger Monday always has that nice 'ring' to it ;) Thanks. Good trading and glta. https://whalewisdom.com/stock/rna

0 · Reply

Market Cap	268.24B
Revenue (ttm)	51.72B
Net Income (ttm)	11.94B
EPS (ttm)	N/A
PE Ratio	14.51
Forward PE	14.09
Profit Margin	23.09%
Debt to Equity Ratio	0.73

Volume	1,339,300
Avg Vol	1,657,078
Day's Range	N/A - N/A
Shares Out	2.11B
Stochastic %K	89%
Beta	0.62
Analysts	Sell
Price Target	$117.71